This site is intended for health professionals only
Tuesday 18 December 2018
Share |

Topic: Allergy

December 17, 2018
There are scant data that describe how often pregnant women deliberately stop eating a specific food item in order to prevent future food allergies in their newborns
Pregnant women routinely swear off alcohol and tobacco to boost their chances of having a healthy baby. What about common food allergens like nuts and milk?
 
December 17, 2018
The researchers hope the Pediatric Asthma Risk Score will become the most common tool used by medical practitioners to predict asthma and help prevent the common airway disease from developing
Scientists at Cincinnati Children's Hospital Medical Center in the US have created and tested a decision tool that appears to be the most accurate, non-invasive method yet developed to predict asthma in young children.
 
The researchers hope the Pediatric Asthma Risk Score (PARS) will become the most common tool used by medical practitioners to predict asthma and help prevent the common airway disease from developing.
 
December 6, 2018
Nexvax2 is currently the only disease-modifying therapeutic in clinical development for patients with coeliac disease
December 4, 2018
The researchers used a next-generation peptide-based immunoassay to subdivide allergenic milk proteins into smaller peptide fragments — called epitopes — and measured the reactivity of the epitopes to a patient’s IgE/IgG4 antibodies
AllerGenis has reported research results in The Journal of Allergy and Clinical Immunology(JACI) that demonstrate the ability to predict, with significant accuracy, milk allergy patients’ outcomes before milk oral immunotherapy treatment (Milk-OIT) is administered, using the company’s novel milk allergy diagnostic assay.  
 
December 3, 2018
The study explored how different exposures during pregnancy, birth or childhood modulate asthma-related immune responses in children
The prevalence of allergic diseases has increased significantly over the last decades, creating substantial financial and societal burdens. Due to this, researchers are trying to discover new approaches to the prevention and treatment of these diseases. 
 
A new PhD thesis from the University of Eastern Finland shows that there is a link between immune responses and diverse early life exposures, such as obstetric factors, farm dust and air pollution. Some changes in immune responses are visible up until adolescence.
December 1, 2018
An international research team has discovered that the parvalbumin protein that usually triggers allergy is much less allergenic in cartilaginous fish than in bony fish
Fish allergy is one of the most dangerous food allergies, as it is often associated with potentially life-threatening symptoms such as anaphylactic shock.
 
November 22, 2018
AR101 slowly builds up tolerance to peanut allergy, study finds

A new oral biologic drug could reduce the risk of allergic reaction in children and adolescents following accidental peanut exposures, research has shown.
 
AR101 slowly builds up tolerance to peanut allergy, a study published in The New England Journal of Medicine found.
 

November 20, 2018
PALISADE (Peanut Allergy oral Immunotherapy Study of AR101 for Desensitization) was an international, randomised (3:1), double-blind, placebo-controlled, Phase III trial to evaluate the efficacy and safety of AR101 in patients with peanut allergy

Aimmune Therapeutics has announced that the New England Journal of Medicinehas published the full results of the landmark Phase III PALISADE clinical trial of AR101, Aimmune’s investigational biologic oral immunotherapy for desensitisation of patients with peanut allergy. PALISADE is the largest and first successful Phase III peanut allergy immunotherapy trial to date.

October 17, 2018
Pharmacists must implement new validation processes from today (17 October) to prioritise the limited stocks of EpiPen junior 150 microgram (mcg), the Department of Health and Social Care (DHSC) and NHS England have said.

Pharmacists must implement new validation processes from today (17 October) to prioritise the limited stocks of EpiPen junior 150 microgram (mcg), the Department of Health and Social Care (DHSC) and NHS England have said.

Following ‘critical’ shortages of the device, the DHSC and NHS England asked pharmacists to validate both private and NHS prescriptions before ordering and supplying the device to a patient.

October 17, 2018
The researchers found clues as to why the allergy immunisation takes so long and how the chances of success can be determined at a very early stage
Allergen-specific immunotherapy can make everyday life much more pleasant for allergy sufferers and provide long-term protection against asthma. It is unclear, however, what exactly happens during this treatment. 
 
October 2, 2018
Patients with severe allergies can use certain batches of EpiPen four months after their expiry date, the Government has said.

Patients with severe allergies can use certain batches of EpiPen four months after their expiry date, the Government has said.
 
In a supply alert issued last week (28 September), the Department of Health and Social Care (DHSC) said that patients can use some batches of EpiPen and EpiPen Junior, due to "limited availability for the remainder of 2018".
 
"Limited availability"
 

October 2, 2018
Patients with severe allergies can use certain batches of EpiPen four months after their expiry date, the Government has said.

Patients with severe allergies can use certain batches of EpiPen four months after their expiry date, the Government has said.
 
In a supply alert issued last week (28 September), the Department of Health and Social Care (DHSC) said that patients can use some batches of EpiPen and EpiPen Junior, due to "limited availability for the remainder of 2018".
 
"Limited availability"
 

May 17, 2018
Public health scheme aims to improve awareness of atopic dermatitis

A scheme to raise awareness about the emotional and physical impact of the most common type of eczema has been launched by a leading charity and a global biopharmaceutical company this month.

February 26, 2018
A preventative treatment for peanut allergies, one of the most severe food allergies, has been developed by San Francisco-based Aimmune Therapeutics and could be the world’s first approved drug for this condition

Sensitivity to peanuts is one of the most dangerous food allergies. Even the smallest traces can cause severe allergic reactions, which can be fatal. The allergy is also relatively common; an estimated 250,000 children in England alone are allergic to peanuts, with rates are on the rise. Peanut allergies are also highly persistent and four out of five children with peanut allergies remain allergic into adulthood.

September 26, 2017
In particular, the guideline establishes the role of new molecular-based component-specific IgE testing as part of a comprehensive approach to diagnosis

 

A new guideline published by the Standards of Care Committee of the British Society for Allergy & Clinical Immunology (BSACI) aims to bring together the latest science in order to improve the diagnosis and management of peanut and tree nut allergy.1

August 9, 2017
Allergen component-resolved diagnostic testing is a new methodology in clinical allergy diagnosis, improving the ability to identify specific clinical phenotypes
July 21, 2017
Humanised IL-5 antagonist monoclonal antibody for add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment

Teva Pharmaceutical Industries Ltd has announced that the National Institute for Health and Care Excellence (NICE) in England has recommended Cinqaero® (reslizumab) in its Final Appraisal Determination (FAD).

July 7, 2017
The guidance will overall assist healthcare professionals by alerting them to the possibility that their patient has rhinitis by aiding accurate diagnosis of the kind of rhinitis – and if allergic, of how to work out which allergen(s) matter
The Standards of Care Committee of the British Society for Allergy & Clinical Immunology (BSACI) has published updated guidance on the diagnosis and management of allergic and non-allergic rhinitis.
 
Allergic rhinitis is common and affects between 10-15% of children and 26% of adults in the UK.
 
September 30, 2015
Work, social and family life all affected by severe asthma, many people report feelings of anxiety, depression and isolation as well

Boston Scientific revealed results of a comprehensive survey, which shows the true burden of severe asthma and the daily challenges faced by people with asthma in Europe. Uncovering Asthma, a survey of over 850 people with severe asthma from across Europe, has found that severe asthma affects a quarter of the respondents on a daily basis, with a staggering 71% feeling the negative effects weekly.

August 10, 2015
Dymista contains azelastine and fluticasone and is a new fast-acting treatment for the management of allergic and perennial rhinitis

 

November 29, 2014
Although allergic rhinitis is usually associated with primary care, it can appear in secondary care, and clinicians and pharmacists need to know how to act when it does

Glenis K Scadding MA MD FRCP
Consultant Rhinologist and Allergist, Royal National Throat, Nose and Ear Hospital
London, UK

Allergic rhinitis is caused by IgE-mediated inflammation in the nasal lining following allergen exposure. It represents a global health problem since some 10–25% of the population are affected,1,2 and the prevalence is increasing. It is classified as a major chronic respiratory disease and is a risk factor for asthma.4

June 13, 2014
The REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey provides the largest pan-European data on incidence of exacerbations and symptoms, levels of Global Initiative for Asthma (GINA)-defined control, as well as insights into patient attitudes

Data from the REALISE™ survey highlight a high incidence of recent exacerbations, even among patients whose asthma is controlled according to clinical guidelines.1

September 24, 2012
MEDA Pharmaceuticals UK Ltd, has just announced the license approval of its newly designed EpiPen® and EpiPen® Jr (Adrenaline) Auto-Injector (0.3 and 0.15 mg adrenaline) device. Whilst the familiar administration technique and actual adrenaline remains unchanged, the new look device has been developed following consultation with patients and healthcare professionals and is designed to improve correct administration and patient safety.
MEDA Pharmaceuticals UK Ltd, has just announced the license approval of its newly designed EpiPen® and EpiPen® Jr (Adrenaline) Auto-Injector (0.3 and 0.15 mg adrenaline) device.
April 14, 2011
Patients with difficult asthma consume a disproportionate amount of resources for what should be an easily treatable condition. A systematic approach that takes into account accurate diagnosis, co-existing conditions and other factors, including medication adherence, helps to ensure appropriate treatment

Anna C Murphy MSc MRPharmS 

Consultant Respiratory Pharmacist, University Hospitals of Leicester NHS Trust, Leicester, UK

Asthma is one of the most common chronic conditions worldwide, affecting about 300 million people of all ages and is estimated to account for about one of every 250 deaths.1